<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602353</url>
  </required_header>
  <id_info>
    <org_study_id>LEAD-PhII-050</org_study_id>
    <nct_id>NCT02602353</nct_id>
  </id_info>
  <brief_title>Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Parallel-Group and Placebo-Controlled Pilot Study to Assess the Safety and Efficacy of a New Pain Patch Versus Placebo and No Treatment for the Treatment of Delayed Onset Muscle Soreness (DOMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lead Chemical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardinal Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lead Chemical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the analgesic efficacy and safety of a new pain
      patch compared to placebo and no treatment in subjects experiencing Delayed Onset Muscle
      Soreness (DOMS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of pain intensity differences over 24 hours from baseline (SPID 24) with movement</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences over 24 hours from baseline (SPID 24) at rest</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences over 48 hours from baseline (SPID 48) with movement</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences over 48 hours from baseline (SPID 48) at rest</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of first perceptible pain relief</measure>
    <time_frame>First 4 hours after Dose 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of meaningful pain relief</measure>
    <time_frame>First 4 hours after Dose 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects global impression of medication</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Delayed Onset Muscle Soreness</condition>
  <arm_group>
    <arm_group_label>Loxoprofen Pain Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Active Pain Patch containing loxoprofen applied once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One Placebo Patch applied once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No Treatment for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxoprofen Pain Patch</intervention_name>
    <description>One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days</description>
    <arm_group_label>Loxoprofen Pain Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>One Placebo Patch applied daily for 3 days</description>
    <arm_group_label>Placebo Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Treatment</intervention_name>
    <description>No Treatment for 3 days</description>
    <arm_group_label>No Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, 18 to 40 years of age

          -  are in good general health, with a BMI less than or equal to 32, and able to perform
             the exercise regimen

          -  develops muscle pain/soreness within 24-48 hours of the end of the exercise regimen
             and have a baseline muscle pain/soreness with movement of greater than or equal to 5
             on the Numerical Rating Scale (NRS) (numerical rating scale) and at least &quot;moderate&quot;
             on the categorical scale

        Exclusion Criteria:

          -  has engaged in upper extremity exercise for a minimum of 6 months prior to study
             participation

          -  has been working heavy manual or physical labor jobs within 3 months prior to study
             participation.

          -  has a known history of allergic reaction or clinically significant intolerance to
             acetaminophen, aspirin, or any nonsteroidal anti-inflammatory drugs

          -  has skin lesions such as psoriasis at the application site

          -  has abnormal skin condition such as eczema, contact dermatitis, pigment anomaly, etc.

          -  has an allergy-related skin condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Muse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <disposition_first_submitted>October 25, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2016</disposition_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

